Subscribe
testing / Shutterstock.com
4 March 2025NewsBig PharmaMuireann Bolger

Teva can’t revive Orange book inhaler battle at Fed Circ

Federal Circuit says only patents claiming the active ingredient of a drug are eligible for listing | Injunction against Teva temporarily paused in January pending the appeal court’s decision to review.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circ grants Teva temporary pause in Orange Book feud
23 January 2025   Teva insisted panel’s narrow interpretation of ‘claims the drug’ will have a seismic effect on the Orange Book | Stay granted while en banc rehearing is under question | Decision could reshape patent listing standards and impact the availability of generic drugs.


Editor's picks

Americas
LSPN finalists revealed for first-ever US awards
3 March 2025

Editor's picks

Americas
LSPN finalists revealed for first-ever US awards
3 March 2025
Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025
Americas
Regeneron holds off copies of $6bn eye treatment
4 February 2025
Careers
Bristows appoints Irish patent attorney to boost UPC representation
4 February 2025
Americas
New national rankings recognise top US patent firms and lawyers
4 February 2025
Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025

More on this story

Americas
Fed Circ grants Teva temporary pause in Orange Book feud
23 January 2025   Teva insisted panel’s narrow interpretation of ‘claims the drug’ will have a seismic effect on the Orange Book | Stay granted while en banc rehearing is under question | Decision could reshape patent listing standards and impact the availability of generic drugs.

More on this story

Americas
Fed Circ grants Teva temporary pause in Orange Book feud
23 January 2025   Teva insisted panel’s narrow interpretation of ‘claims the drug’ will have a seismic effect on the Orange Book | Stay granted while en banc rehearing is under question | Decision could reshape patent listing standards and impact the availability of generic drugs.

More features

Jones Day adds experienced patent litigators from Weil
WIPR Leaders revamps selection process for 2025 edition
La Prairie accused of stealing caviar biotech for luxury skincare line
LSPN finalists revealed for first-ever US awards
Amy Candido to head IP litigation team at Simpson Thacher
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
The rise of weight loss drugs: Regulators tighten up
Paul Hastings adds Latham tech transactions expert as co-chair